Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

0(0%)

Results Posted

20%(1 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_3

17%

Ph phase_2

17%

Ph not_applicable

33%

Ph phase_4

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

1(20.0%)

Phase 3Large-scale testing

1(20.0%)

Phase 4Post-market surveillance

1(20.0%)

N/ANon-phased studies

2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Terminated(1)

Detailed Status

Completed5

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (20.0%)

Phase 31 (20.0%)

Phase 41 (20.0%)

N/A2 (40.0%)

Trials by Status

terminated117%

completed583%

Recent Activity

0 active trials

Showing 5 of 6

completed

Clinical Trials (6)

Showing 6 of 6 trials

NCT03304652

Cerebral MRI During Sleep

Completed

NCT03489304Phase 2

Zaleplon in HIV Patients With Depression

Completed

NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated

NCT00694317Not Applicable

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions

Completed

NCT00694187Not Applicable

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions

Completed

NCT01159652Phase 4

Hypnotic Medications and Memory: Effect of Drug Exposure During the Night

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6